Does hs-CRP predict the severity of cardiovascular disease and chronic kidney disease?
Not Applicable
- Conditions
- Health Condition 1: I702- Atherosclerosis of native arteriesof the extremitiesHealth Condition 2: I251- Atherosclerotic heart disease of native coronary arteryHealth Condition 3: I639- Cerebral infarction, unspecifiedHealth Condition 4: N189- Chronic kidney disease, unspecified
- Registration Number
- CTRI/2023/03/050262
- Lead Sponsor
- MANIPAL ACADEMY OF HIGHER EDUCATIO
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Yet Recruiting
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
Evidence of ASCVD and CKD stage 3 or stage 4
Exclusion Criteria
Clinical evidence of, or suspicion of active infection, myocardial infarction, stroke, hospitalization for unstable angina pectoris, or transient ischemic attack within 30 days prior to recruitment
Planned coronary, carotid, or peripheral artery revascularization known on the day of screening
Major cardiac surgical, non-cardiac surgical, or major endoscopic procedure (thoracoscopic or laparoscopic) within the past 30 days prior to recruitment or any major surgical procedure planned at the time of recruitment
hsCRP levels of more than 20 are excluded and reassessed later about including patients in the study
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Prevalence of elevated hs-CRP levels in established ASCVD and CKD <br/ ><br>Identifying the relationship between raised levels of hs-CRP and other biochemical parameters among the sub-group population with established ASCVD <br/ ><br>Timepoint: at the time of collection
- Secondary Outcome Measures
Name Time Method Identifying the association of clinical and physical parameters with hs-CRP levels in patients with established ASCVD <br/ ><br>Co-relation between hs-CRP and MACE rate on total 12 months, follow-up of patients with documented ASCVD on standard medical therapy <br/ ><br>Adverse renal events <br/ ><br>Timepoint: 12 months